Literature DB >> 9736425

Expression of p21 (Waf1/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression.

M G van Oijen1, M G Tilanus, R H Medema, P J Slootweg.   

Abstract

p21(Waf1/Cipl) is a critical downstream effector in the p53-dependent pathway of growth control and causes growth arrest through inhibition of cyclin-dependent kinases. In this study 67% of 43 head and neck squamous cell carcinoma (HNSCC) and 60% of 15 tumour-adjacent oral dysplasias overexpressed p21 by immunohistochemical staining. Overexpression of p21 in HNSCC was independent of the presence of functional p53, as assessed by analysis of mutations and loss of heterozygosity and by immunohistochemisty. Rather, the expression pattern of p21 was associated with differentiation. Furthermore, in most tumours, the p21 positive cells did not incorporate bromodeoxyuridine (BrdU), which indicates inhibition of proliferation by p21 in these cells. In some tumours, p21 was also expressed in proliferating cells. In these latter tumour cells, cyclin D1 was frequently expressed as well. Therefore, we suggest that expression of cyclin D1 might overcome the inhibitory effect of p21 in these cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736425     DOI: 10.1111/j.1600-0714.1998.tb01969.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  9 in total

1.  DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines.

Authors:  Maki Ikeda; Akira Kurose; Eriko Takatori; Toru Sugiyama; Frank Traganos; Zbigniew Darzynkiewicz; Takashi Sawai
Journal:  Int J Oncol       Date:  2010-05       Impact factor: 5.650

2.  Gene expression of miRNA-138 and cyclin D1 in oral lichen planus.

Authors:  Noha A Ghallab; Rehab Fawzy Kasem; Safa Fathy Abd El-Ghani; Olfat G Shaker
Journal:  Clin Oral Investig       Date:  2017-03-08       Impact factor: 3.573

3.  Sensitivity to the non-COX inhibiting celecoxib derivative, OSU03012, is p21(WAF1/CIP1) dependent.

Authors:  Haiming Ding; Chunhua Han; Dongmei Guo; Dasheng Wang; Wenrui Duan; Ching-Shih Chen; Steven M D'Ambrosio
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

4.  Expression of the cell cycle regulation proteins p53 and p21WAF1 in different types of non-dysplastic leukoplakias.

Authors:  Fernanda Visioli; Isabel Silva Lauxen; Manoel Sant'ana Filho; Pantelis Varvaki Rados
Journal:  J Appl Oral Sci       Date:  2012 May-Jun       Impact factor: 2.698

Review 5.  The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy.

Authors:  Nina-Naomi Kreis; Frank Louwen; Juping Yuan
Journal:  Cancers (Basel)       Date:  2019-08-21       Impact factor: 6.639

6.  RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence.

Authors:  Joseph L Regan; Dirk Schumacher; Stephanie Staudte; Andreas Steffen; Ralf Lesche; Joern Toedling; Thibaud Jourdan; Johannes Haybaeck; Dominik Mumberg; David Henderson; Balázs Győrffy; Christian R A Regenbrecht; Ulrich Keilholz; Reinhold Schäfer; Martin Lange
Journal:  iScience       Date:  2021-05-24

Review 7.  The role of p21Waf1/CIP1 as a Cip/Kip type cell-cycle regulator in oral squamous cell carcinoma (Review).

Authors:  Mario Pérez-Sayáns; José-Manuel Suárez-Peñaranda; Pilar Gayoso-Diz; Francisco Barros-Angueira; José-Manuel Gándara-Rey; Abel García-García
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2013-03-01

8.  Stabilization of p21 by mTORC1/4E-BP1 predicts clinical outcome of head and neck cancers.

Authors:  Susana Llanos; Juana M García-Pedrero; Lucia Morgado-Palacin; Juan P Rodrigo; Manuel Serrano
Journal:  Nat Commun       Date:  2016-02-02       Impact factor: 14.919

Review 9.  The Role of Cell Cycle Regulators in Cell Survival-Dual Functions of Cyclin-Dependent Kinase 20 and p21Cip1/Waf1.

Authors:  Lo Lai; Ga Yoon Shin; Hongyu Qiu
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.